ADHD Therapeutics: Market Research Report
This report analyzes the worldwide markets for ADHD Therapeutics in US$ Million.
The report provides separate comprehensive analytics for the US and Rest of World.
Annual estimates and forecasts are provided for each region for the period of 2006 through 2015.
The report profiles 27 companies including many key and niche players such as Eli Lilly & Company, Johnson & Johnson, Janssen-Cilag, Novartis AG, Shire Plc, UCB S.A., Companies with Drugs in Pipeline for ADHD: Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc., KemPharm, Inc., and NeuroSearch A/S.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
The report provides separate comprehensive analytics for the US and Rest of World.
Annual estimates and forecasts are provided for each region for the period of 2006 through 2015.
The report profiles 27 companies including many key and niche players such as Eli Lilly & Company, Johnson & Johnson, Janssen-Cilag, Novartis AG, Shire Plc, UCB S.A., Companies with Drugs in Pipeline for ADHD: Abbott Laboratories, Inc., Cortex Pharmaceuticals, Inc., KemPharm, Inc., and NeuroSearch A/S.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITION
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
A Prelude
Lack of Awareness – A Major Impediment
Adult ADHD – A Growing Market Opportunity
Unfulfilled Needs Provide Impetus to Develop New Molecules
Safety Concerns Foster Research in Non Stimulant Segment
Presence of Co-morbidities with ADHD Creates Opportunities for Combination Therapies
Introduction of Generics Shakes Market
Patent Expiries of Major Drugs in the ADHD Market
2.COMPETITIVE SCENARIO
Shire Leads the Way
J&J’s Concerta – Leading Drug for ADHD by Default
Eli Lilly’s Strattera – Creating a Niche
Novartis Retains Market Share
Pipeline Drugs
3.THE ADHD CONUNDRUM
ADHD – A Disorder or Marketing Gimmick of Pharmaceutical Companies?
Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
Differences in Diagnostic Criteria in Europe and US
Hiccups in the Way
ADHD in Women
4.ADHD – AN INSIGHT
Attention Deficit Hyperactivity Disorder (ADHD) – Introduction
Brief History of the Disorder
Common Co-Occurring Disorders With ADHD
Consequences of ADHD
What Leads to ADHD?
Study Reveals Deficits in Protein Levels in Brain’s Reward/Motivation System
ADHD Symptoms
DSM IV Criteria for Diagnosis of ADHD
DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity
Types of ADHD
Treating ADHD
Stimulants
Non-stimulants
Others
5.REVIEW OF SELECT DRUGS
ADHD Drugs – Background
Brand Review
Ritalin LA
Focalin
Concerta
Strattera
Metadate CD
Adderall XR
Daytrana
Vyvanse
Intuniv
6.RESEARCH PIPELINE
Supernus Pharmaceuticals’ SPN 810 Proves Successful in Phase IIa Clinical Trials
KemPharm Announces Completion of Phase I Trials of KP106
Shire Announces Results of Phase IIIb Clinical Trials of Daytrana® in Adolescents
Addrenex and Sciele Pharma Submit sNDA for Clonicel for ADHD Treatment
Targacept Collaborates with AstraZeneca for AZD3480 Clinical Trials
Neptune Technologies Announces Positive Reports on Pre-Clinical Trials of Medical Food Candidate for Treatment of ADHD
NeuroSearch Completes Phase II Studies on Efficacy and Security of ABT-894 in Adults with ADHD
Abbott Announces Positive Results From Phase II Studies of a Novel Approach of Treating ADHD
7.PRODUCT LAUNCHES/INTRODUCTIONS
Shire Unveils First Prodrug Therapy for ADHD in Canadian Market
Teva Launches First Authorized Generic Version of Adderall XR® Capsules
Shire Introduces INTUNIV™
Eli Lilly Japan Introduces Strattera in the Country
8.RECENT INDUSTRY ACTIVITY
Avacta Group Acquires TheraGenetics
AstraZeneca Grants Interim Payment to Targacept
Addrenex Pharmaceuticals Inks Agreement with Dream Pharma
Durect Signs Agreement with Orient Pharma
Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical
Shire Receives FDA Approval for INTUNIV Tablets
Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for Vyvanse
Shire Pharmaceuticals Establishes Office in Tokyo
Shire and UCB Enter into Agreement
Shire Retains Exclusivity for Vyvanse
Shire Settles Litigation with Sandoz for Generic Adderall
Sciele Pharma to Takeover Addrenex Pharmaceuticals
Auriga Laboratories Receives Approval from FDA for LiquaddTM
Concerta Extended Release Tablets Receive US FDA Approval for Use in Adult Treatment
Eurand Enters into Settlement with UCB
Paladin Labs Secures Dexedrine's Distribution Rights from GlaxoSmithKline
Shire Receives Approval from FDA for Use of Vyvanse in Adults
Strattera Receives FDA Approval for Maintenance of ADHD in Children & Adolescents
The Dore Group Providing Alternate ADHD Treatment to Drugs Goes Into Liquidation
Shire Takes Over New River Pharmaceuticals to Gain Full Control Over Vyvanse™
9.FOCUS ON SELECT PLAYERS
Eli Lilly & Company (USA)
Johnson & Johnson (USA)
Janssen-Cilag (Switzerland)
Novartis AG (Switzerland)
Shire Plc (The UK)
UCB S.A. (Belgium)
Companies with Drugs in Pipeline for ADHD
Abbott Laboratories, Inc. (USA)
Cortex Pharmaceuticals, Inc. (US)
KemPharm, Inc. (USA)
NeuroSearch A/S (Denmark)
10.GLOBAL MARKET PERSPECTIVE
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current and Future Analysis
ADHD Epidemic in the US !
Causes for Widespread ADHD Diagnosis and Treatment in the US
ADHD Drugs Combat Safety Concerns
Market Exhibits Greater Potential
Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
Cyclical Nature of ADHD Market
Competitive Scenario
Product Launches
Strategic Corporate Developments
Select Players
B. MARKET ANALYTICS
2.REST OF WORLD
A. MARKET ANALYSIS
Current and Future Analysis
Review of Select Markets
Canada
Concerta Leads the Market
Europe
Germany
The United Kingdom
Australia
Product Launches
Strategic Corporate Developments
Select Players
B. MARKET ANALYTICS
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 27 (including Divisions/Subsidiaries - 33)
Region/CountryPlayers
The United States
Japan
Europe
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
A Prelude
Lack of Awareness – A Major Impediment
Adult ADHD – A Growing Market Opportunity
Table 1. Market Share of ADHD Prescriptions by Age Category: Children, Adolescents and Adults (includes corresponding Graph/Chart)
Unfulfilled Needs Provide Impetus to Develop New Molecules
Safety Concerns Foster Research in Non Stimulant Segment
Presence of Co-morbidities with ADHD Creates Opportunities for Combination Therapies
Introduction of Generics Shakes Market
Patent Expiries of Major Drugs in the ADHD Market
2.COMPETITIVE SCENARIO
Table 2. Leading Brands in the Global ADHD Market by Prescription Share (2008) (includes corresponding Graph/Chart)
Shire Leads the Way
J&J’s Concerta – Leading Drug for ADHD by Default
Eli Lilly’s Strattera – Creating a Niche
Novartis Retains Market Share
Pipeline Drugs
3.THE ADHD CONUNDRUM
ADHD – A Disorder or Marketing Gimmick of Pharmaceutical Companies?
Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
Differences in Diagnostic Criteria in Europe and US
Hiccups in the Way
ADHD in Women
4.ADHD – AN INSIGHT
Attention Deficit Hyperactivity Disorder (ADHD) – Introduction
Brief History of the Disorder
Common Co-Occurring Disorders With ADHD
Consequences of ADHD
What Leads to ADHD?
Study Reveals Deficits in Protein Levels in Brain’s Reward/Motivation System
ADHD Symptoms
DSM IV Criteria for Diagnosis of ADHD
DSM IV Criteria for Inattention and Hyperactivity/ Impulsivity
Types of ADHD
Treating ADHD
Stimulants
Non-stimulants
Others
5.REVIEW OF SELECT DRUGS
ADHD Drugs – Background
Brand Review
Ritalin LA
Focalin
Table 3. Global Revenues of Novartis’ ADHD Drugs - Ritalin/Focalin (2008-2009) (in US$ million)
Concerta
Table 4. Global Revenues of Concerta (2006-2009) (includes corresponding Graph/Chart)
Strattera
Table 5. Global Revenues of Strattera (2006-2009) (in US$ million) (includes corresponding Graph/Chart)
Metadate CD
Table 6. Global Revenues of Metadate CD/Equasym (2007-2008) (in €Million)
Adderall XR
Table 7. Global Revenues of Adderall XR (2006-2009) (in US$ million) (includes corresponding Graph/Chart)
Daytrana
Table 8. Global Revenues of Daytrana (2006-2009) (in US$ million) (includes corresponding Graph/Chart)
Vyvanse
Table 9. Global Revenues of Vyvanse (2007-2009) (in US$ million) (includes corresponding Graph/Chart)
Intuniv
6.RESEARCH PIPELINE
Supernus Pharmaceuticals’ SPN 810 Proves Successful in Phase IIa Clinical Trials
KemPharm Announces Completion of Phase I Trials of KP106
Shire Announces Results of Phase IIIb Clinical Trials of Daytrana® in Adolescents
Addrenex and Sciele Pharma Submit sNDA for Clonicel for ADHD Treatment
Targacept Collaborates with AstraZeneca for AZD3480 Clinical Trials
Neptune Technologies Announces Positive Reports on Pre-Clinical Trials of Medical Food Candidate for Treatment of ADHD
NeuroSearch Completes Phase II Studies on Efficacy and Security of ABT-894 in Adults with ADHD
Abbott Announces Positive Results From Phase II Studies of a Novel Approach of Treating ADHD
7.PRODUCT LAUNCHES/INTRODUCTIONS
Shire Unveils First Prodrug Therapy for ADHD in Canadian Market
Teva Launches First Authorized Generic Version of Adderall XR® Capsules
Shire Introduces INTUNIV™
Eli Lilly Japan Introduces Strattera in the Country
8.RECENT INDUSTRY ACTIVITY
Avacta Group Acquires TheraGenetics
AstraZeneca Grants Interim Payment to Targacept
Addrenex Pharmaceuticals Inks Agreement with Dream Pharma
Durect Signs Agreement with Orient Pharma
Hisamitsu Pharmaceutical Acquires Noven Pharmaceutical
Shire Receives FDA Approval for INTUNIV Tablets
Shire Pharmaceuticals and GSK Sign a Co-Promotion Deal for Vyvanse
Shire Pharmaceuticals Establishes Office in Tokyo
Shire and UCB Enter into Agreement
Shire Retains Exclusivity for Vyvanse
Shire Settles Litigation with Sandoz for Generic Adderall
Sciele Pharma to Takeover Addrenex Pharmaceuticals
Auriga Laboratories Receives Approval from FDA for LiquaddTM
Concerta Extended Release Tablets Receive US FDA Approval for Use in Adult Treatment
Eurand Enters into Settlement with UCB
Paladin Labs Secures Dexedrine's Distribution Rights from GlaxoSmithKline
Shire Receives Approval from FDA for Use of Vyvanse in Adults
Strattera Receives FDA Approval for Maintenance of ADHD in Children & Adolescents
The Dore Group Providing Alternate ADHD Treatment to Drugs Goes Into Liquidation
Shire Takes Over New River Pharmaceuticals to Gain Full Control Over Vyvanse™
9.FOCUS ON SELECT PLAYERS
Eli Lilly & Company (USA)
Johnson & Johnson (USA)
Janssen-Cilag (Switzerland)
Novartis AG (Switzerland)
Shire Plc (The UK)
UCB S.A. (Belgium)
Companies with Drugs in Pipeline for ADHD
Abbott Laboratories, Inc. (USA)
Cortex Pharmaceuticals, Inc. (US)
KemPharm, Inc. (USA)
NeuroSearch A/S (Denmark)
10.GLOBAL MARKET PERSPECTIVE
Table 10. World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 11. World 10 -Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Market by Geographic Region – Percentage Breakdown of Revenues for US and Rest of World Markets for Years 2006, 2009 and 2015
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current and Future Analysis
ADHD Epidemic in the US !
Table 12. Prevalence Rate of ADHD in Different Backgrounds According to Age, Ethnicity, Gender and Family Structure in the US in 2007
Causes for Widespread ADHD Diagnosis and Treatment in the US
ADHD Drugs Combat Safety Concerns
Market Exhibits Greater Potential
Table 13. Percentage Share of ADHD Prescriptions in US by Patient Category - Children, Adolescents and Adults (2002 and 2007) (includes corresponding Graph/Chart)
Lack of Clear Guidelines and Criteria for Adult Diagnosis Hampers Market
Cyclical Nature of ADHD Market
Competitive Scenario
Table 14. Leading Players and Drug Brands in the US ADHD Market (2007, 2008) : Percentage Breakdown of Prescriptions for Shire, McNeil Janssen, Eli Lilly, Novartis, Celltech, Pharmaceuticals / UCB, and Others (includes corresponding Graph/Chart)
Product Launches
Strategic Corporate Developments
Select Players
B. MARKET ANALYTICS
Table 15. US Recent Past, Current & Future Analysis for Sales Force Automation (SFA) Market Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2.REST OF WORLD
A. MARKET ANALYSIS
Current and Future Analysis
Review of Select Markets
Canada
Concerta Leads the Market
Table 16. Leading Drug Brands in the Canadian ADHD Market (2008): Percentage Share Breakdown of Revenues for Concerta, Adderall, Dexedrine, Generics, and Others (includes corresponding Graph/Chart)
Europe
Germany
Table 17. Prevalence Rates of ADHD in Germany in Terms of Gender, Age and Socioeconomic Status Reimbursement Policy
The United Kingdom
Australia
Product Launches
Strategic Corporate Developments
Select Players
B. MARKET ANALYTICS
Table 18. Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Drugs Analyzed with Annual Revenues in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 27 (including Divisions/Subsidiaries - 33)
Region/CountryPlayers
The United States
Japan
Europe
Germany
The United Kingdom
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle-East
